Outcomes in Decision Analysis: Utilities, QALYs, and Discounting Aaron B. Caughey, MD, PhD Associate Professor in Residence Director,

Slides:



Advertisements
Similar presentations
Elicitation methods Health care demands exceed resource supply Therefore, rationing is inevitable Many ways by which we can ration health care One is economic.
Advertisements

HEA PTP: M207 Health Economics1 Measurement & Valuation of Health What is health? Why do we need to measure it? How can it be measured? Why do we need.
Disability Adjusted Life Years Possibilities and Problems Trude M. Arnesen, Ole Frithjof Norheim.
1 QOL in oncology clinical trials: Now that we have the data what do we do?
MANAGERIAL ACCOUNTING
INVESTMENT APPRAISAL NON DISCOUNTING By Lucky Yona.
Scaling Session Measurement implies “assigning numbers to objects or events…” Distinguish two levels: we can assign numbers to the response levels for.
Evaluation of Training
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
Lecture 1: Decision analysis UCSF DCEA 2004 Objectives  To understand what decision analysis is and when it might be used  To understand the sequence.
Decision Analysis. What is decision analysis? Based on expected utility theory Based on expected utility theory Used in conditions of uncertainty Used.
4. Project Investment Decision-Making
Decision Analysis: Utilities and QALYs Miriam Kuppermann, PhD, MPH Professor Departments of Obstetrics, Gynecology & Reproductive Sciences and Epidemiology.
Summary Measures of Population Health: Measuring the impact of disease, injuries and risk factors.
Judgment and Decision Making in Information Systems Utility Functions, Utility Elicitation, and Risk Attitudes Yuval Shahar, M.D., Ph.D.
Alternative antiretroviral monitoring strategies for HIV-infected patients in resource-limited settings: Opportunities to save more lives? R Scott Braithwaite,
Introduction to decision modelling Andrew Sutton.
Utility Assessment HINF Medical Methodologies Session 4.
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Uncertainty and Consumer Behavior
1 Value of Life Analysis Scott Matthews Courses: / /
A RECIPE FOR INCOHERENCE: AVERAGING TIME-TRADEOFF OR STANDARD-GAMBLE UTILITIES ACROSS HEALTH ATTRIBUTES Gordon B. Hazen, IEMS Department, Northwestern.
1 Civil Systems Planning Benefit/Cost Analysis Scott Matthews Courses: and Lecture /6/2002.
COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS
1 Civil Systems Planning Benefit/Cost Analysis Scott Matthews Courses: and Lecture /5/2003.
QUALITY OF LIFE ASSESSMENT IN PEOPLE LIVING WITH HIV/AIDS Antonieta Medina Lara HIV/AIDS and STI Knowledge Programme Liverpool School of Tropical Medicine.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
Taxes on the Longevity Dividend: Can we Reduce Them? Lessons from the Theoretical Foundations of Medical Cost-Effectiveness Analysis David Meltzer MD,
Summary of measures of population Health Farid Najafi MD PhD School of Population Health Kermanshah University of Medical Sciences.
Evidence Evaluation & Methods Workgroup: Developing a Decision Analysis Model Lisa A. Prosser, PhD, MS September 23, 2011.
Knowing what you get for what you pay An introduction to cost effectiveness FETP India.
Estimating Outcomes in Decision Analysis Miriam Kuppermann, PhD, MPH Associate Professor Departments of Obstetrics, Gynecology & Reproductive Sciences.
Measuring Health Outcomes
Decision Analysis: Utilities and QALYs Miriam Kuppermann, PhD, MPH Professor Departments of Obstetrics, Gynecology & Reproductive Sciences and Epidemiology.
Hss4303b – intro to epidemiology April 8, 2010 – epidemiology and health policy.
University of Minnesota Medical Technology Evaluation and Market Research Department of Healthcare Management Course: MILI/PUBH 6589 Spring Semester, 2013.
Decision Analysis: What? Why? How? Epi 213 Jan 10, 2013 Dhruv S. Kazi, MD, MSc, MS Assistant Adjunct Professor Division of Cardiology San Francisco General.
317_L26, Mar J. Schaafsma 1 Review of the Last Lecture Are looking at program evaluation in healthcare Three methods: CBA, CEA, CUA discussed CBA,
Estimating Outcomes in Decision Analysis Brian Harris MPP Candidate Goldman School of Public Policy University of California, Berkeley.
Outcomes in Decision Analysis: Utilities, QALYs & DALYs, and Discounting DCEA 24 January 2013 James G. Kahn.
Phaedra Corso, Ph.D. Associate Professor College of Public Health University of Georgia Program Evaluation from an Economic Perspective.
Chapter 2 Risk Measurement and Metrics. Measuring the Outcomes of Uncertainty and Risk Risk is a consequence of uncertainty. Although they are connected,
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
Sample Size Determination in Studies Where Health State Utility Assessments Are Compared Across Groups & Time Barbara H Hanusa 1,2 Christopher R H Hanusa.
PHARMACOECONOMICS Dr. Mohammad Aljawadi, PharmD PhD Department of Clinical Pharmacy King Saud University Aug, 2015 PHCL 431.
Introduction to decision analysis Jouni Tuomisto THL.
Introduction to decision analysis Jouni Tuomisto THL.
HERU is supported by the Chief Scientist Office of the Scottish Executive Health Department and the University of Aberdeen. The author accepts full responsibility.
The financial costs and benefits of alcohol The financial costs and benefits of alcohol Christine Godfrey Department of Health Sciences & Centre for Health.
Decision Analytic Approaches for Evidence-Based Practice M8120 Fall 2001 Suzanne Bakken, RN, DNSc, FAAN School of Nursing & Department of Medical Informatics.
Scaling Session Measurement implies assigning numbers to objects or events. In our case, the numbers “weight” responses to questions, so that saying “Yes”
Cost-Effectiveness and Outcomes Research Setting value to what we do.
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.
EBM --- Journal Reading Presenter :葉麗雯 Date : 2005/10/27.
بسم الله الرحمن الرحيم Community Medicine Lec -11-
Economics of Complementary and Integrative Medicine: Where Do We Go From Here? Patricia M. Herman, ND, PhD, RAND Corporation IM4US Boston August 8, 2014.
IE 485 «Decision Making in Health Care»
Benjamin Kearns, The University of Sheffield
Global burden of diseases
Preference Assessment 1 Measuring Utilities Directly
NAPLEX preparation: Biostatistics
Cost-Effectiveness of Helicopter Versus Ground Emergency Medical Services for Trauma Scene Transport in the United States  M. Kit Delgado, MD, MS, Kristan.
Measuring outcomes Emma Frew October 2012.
Elicitation methods Health care demands exceed resource supply
Presentation transcript:

Outcomes in Decision Analysis: Utilities, QALYs, and Discounting Aaron B. Caughey, MD, PhD Associate Professor in Residence Director, Center for Clinical and Policy Perinatal Research Department of Obstetrics and Gynecology University of California, San Francisco January 14, 2010

Disclosures No personal financial disclosures Research Funding: NIH/NICHD AHRQ – Elective Induction of Labor Robert Wood Johnson Foundation – Cesarean Delivery: Outcomes, Preferences, Costs Hellman Foundation

Overview  Back to the aneurysm example:  To Clip Or Not To Clip?  Clinical Outcomes  Utilities and utility measurement  Standard Gamble  Time Tradeoff  Calculating quality-adjusted life years  Discounting

Review—Last Lecture Formulated an explicit question Formulated an explicit question “to clip or not to clip” (incidental aneurysm ) “to clip or not to clip” (incidental aneurysm ) Made a simple decision tree Made a simple decision tree Conducted an expected value calculation to determine which course of action would likely yield the highest life expectancy Conducted an expected value calculation to determine which course of action would likely yield the highest life expectancy

To Clip or Not To Clip.865 vs.977 =1.0 =.55 =.9825 =.9921 =.977 Diff = =0

To Clip or not to Clip? Has an impact on life expectancy Has an impact on life expectancy Also actual clinical outcomes: Also actual clinical outcomes: Surgical death Surgical death Aneurysm rupture Aneurysm rupture Death from aneurysm rupture Death from aneurysm rupture Neurologic Injury Neurologic Injury Major Major Minor Minor Fear of aneurysm rupture Fear of aneurysm rupture

Quantifying Health Outcomes Mortality Life Years number of expected years of life Significant Morbidity Paralysis, loss of sight Quality Adjusted Life Years Expected life years adjusted for the valuation of the possible states in each year Financial Valuation of these Outcomes Costs to patient, payor, or society Willingness to pay to avoid outcomes, obtain treatment

Health Outcomes – Mortality Mortality Mortality Death from disease/accident/procedure e.g. If Ms. Brooks undergoes surgery, one of the possible outcomes is mortality Life Years Life Years Calculate an expected value of life years using a probabilistically weighted average of expected life e.g. If Ms. Brooks does not undergo surgery, her life expectancy is less than if she did not have aneurysm, these outcomes are measured in expected life years

Health Outcomes – Morbidity Morbidity Morbidity Some health state that is less than perfect e.g. disability from stroke, chronic pain Comparison of morbidities Comparison of morbidities Difficult – apples and oranges problem e.g. which is worse: Blind v. Deaf Deaf v. Paraplegia Paraplegia v. Blind

To Clip or not to Clip? Clinical outcomes for clinician readers Clinical outcomes for clinician readers Outcomes may affect health-related quality of life: how do we compare? Outcomes may affect health-related quality of life: how do we compare? Neurologic injury can cause mild/moderate disability Neurologic injury can cause mild/moderate disability Not clipping can cause anxiety associated with being at risk of aneurysm rupture Not clipping can cause anxiety associated with being at risk of aneurysm rupture Outcomes may occur at different times Outcomes may occur at different times

How do we incorporate quality-of-life effects into DA? Measure/estimate and apply utilities Measure/estimate and apply utilities Use utilities to quality-adjust life expectancy for decision and cost-effectiveness analysis Use utilities to quality-adjust life expectancy for decision and cost-effectiveness analysis

Preview—Where We Are Going with this Analysis? Recall Ms. Brooks and her incidental aneurysm -- to clip or not to clip? We want to: Determine her utilities Determine her utilities Use them to generate QALYs Use them to generate QALYs Evaluate incremental QALYs and cost (CEA/CUA) Evaluate incremental QALYs and cost (CEA/CUA) Compare incremental cost effectiveness ratios (ICER) to other currently accepted medical interventions Compare incremental cost effectiveness ratios (ICER) to other currently accepted medical interventions

What is a Utility? Utility - Quantitative measure of the strength of an individual’s preference for a particular health state or outcome. Utilities can be obtained for: * Disease states (diabetes, depression) * Treatment effects (cure, symptom management) * Side effects (impotence, dry mouth) * Process (undergoing surgery, prenatal diagnostic procedure)

Utilities Utilities are the currency we use to assign values to outcomes Scaled from 0 to 1 1 = perfect or ideal health or health in the absence of the condition being studied 0 = death

How are utilities measured? Utilities are commonly estimated using comparisons to the 0 and 1 anchors Visual Analog Scale Visual Analog Scale Standard Gamble Standard Gamble Time Trade-off Time Trade-off

BKA vs. AKA Example Patient in the hospital has infection of the leg Two options: 1) BKA BKA –1% mortality risk BKA –1% mortality risk 2)Medical management – 20% chance of infection worsening and needing AKA 2)Medical management – 20% chance of infection worsening and needing AKA AKA – above the knee amputation AKA – above the knee amputation 10% mortality risk 10% mortality risk Let’s draw a decision tree

For which outcomes do we need to measure utilities? Death? Death? Risk of worsening? Risk of worsening? Living with part of a leg (below the knee) missing? Living with part of a leg (below the knee) missing? Living with a bigger part of a leg (above the knee) missing? Living with a bigger part of a leg (above the knee) missing? Others? Others?

Visual Analog Scaling Full health: intact leg Dead BKA Outcomes rated on a 0-to-100 “feeling thermometer.” AKA

Standard Gamble What chance of immediate death would you be willing to incur to avoid living with the outcome being assessed? Method relies on respondents choosing between: 1) a certain outcome (BKA) 1) a certain outcome (BKA) 2) a gamble between an ideal outcome (intact leg) and the worst outcome (dead) 2) a gamble between an ideal outcome (intact leg) and the worst outcome (dead)

Standard Gamble Question Death Perfect Health

xercise Standard Gamble Exercise Spend the rest of your life with BKA ] immediate death [p]% chance of immediate death 1-[p]% chance of spending the rest of your life with an intact leg Which do you prefer? Choice AChoice B

Standard Gamble Standard gamble measurement involves questioning patients to determine the p at which the two outcomes are equivalent Using expected utilities, the value of p gives the utility Utility (BKA) x Prob (BKA) = Utility(cure) x (p) + Utility(death) x (1-p) The utility of BKA = p: note P(BKA) = 1 Utility (BKA) = [Utility(cure) x (p) + Utility(death) x (1-p)] = [1.0 x p + 0 x (1-p)] = p

Time Tradeoff How many years of your life would you be willing to give up to spend your remaining life without the condition/health state being assessed? Method relies on respondents choosing between: 1) Full life expectancy with the condition/outcome being assessed (BKA) 1) Full life expectancy with the condition/outcome being assessed (BKA) 2) A reduced life expectancy with the ideal outcome (intact leg) 2) A reduced life expectancy with the ideal outcome (intact leg)

Time Tradeoff Preference Elicitation Spend the remaining 40 years of your life with BKA Live 40 more years of life with an intact leg (give up 0 years of life) Which do you prefer? Choice AChoice B

Time Tradeoff Preference Elicitation Spend the remaining 40 years of your life with BKA Live 30 more years of life with an intact leg (give up 10 years of life) Which do you prefer? Choice AChoice B

Utility Measurement – Time Trade-off Time Trade-off involves patients choosing between: quality of life v. length of time alive When patients are equivocal between choice: Time A * Utility A = Time B * Utility B e.g. If you have a life expectancy of 30 years with a BKA; how much time would you give-up to live in your current state? Would you give up 5 years? 3 years? 1 year? 30 years * Utility (BKA) = (30-x) years * 1.0 If you’re willing to give up 3 years, that means: Utility of BKA = [(30-3)*1/ 30] = 27/30 = 0.9

Pros and Cons - VAS Advantage: Easy to understand Disadvantages: Doesn’t require the respondent to: Think about what they’d be willing to give up Think about what they’d be willing to give up Explore risk preference Explore risk preference Values spread over the range Values spread over the range

Pros and Cons – SG Advantages: Requires assessor to give something up, incorporates risk attitude Disadvantages: Choices may be difficult to make Most confusion-prone method Lack of engagement or willingness to participate in exercise Values tend to cluster near 1

Pros and Cons – TTO Advantages: Still asking assessor to give something up Easier choices than SG. Values not so clustered near 1 Disadvantages: Fails to incorporate risk Lack of clarity of when time traded occurs Isn’t something that one can choose to give up. (One can take on a risk of death, but not “pay with life years.”)

Utilities in decision analysis Utilities can adjust life expectancy in DA where outcomes include morbidity/quality- of-life effects. Utilities can adjust life expectancy in DA where outcomes include morbidity/quality- of-life effects. Quality Adjusted Life-Years (QALYs) Quality Adjusted Life-Years (QALYs)

QALYs QALYs are generally considered the standard unit of comparison for outcomes QALYs are generally considered the standard unit of comparison for outcomes QALYs = time (years) x quality (utility) QALYs = time (years) x quality (utility) e.g. 40 years life expectancy after AKA, e.g. 40 years life expectancy after AKA, utility (AKA) = 0.9 utility (AKA) = 0.9 = 40 x 0.9 = 36 QALYs = 40 x 0.9 = 36 QALYs

Back to aneurysm

.865 vs.977 =1.0 =.55 =.9825 =0 =.9921 =.977 Diff =

Now we want to add utilities for intermediate outcomes Normal survival 1.0 Worry about possibility of aneurysm rupture 0.95 Stroke (clipping complication or aneurysm rupture) ( )/2=0.5 Early death 0.5 Immediate death 0.0

Including utility for early death and stroke=0.5

Adding utility for worry =.95

“Men often, from infirmity of character, make their election for the nearer good, though they know it to be the less valuable”* *Mill JS. Utilitarianism. London: Routledge, 1871 Outcomes - Discounting

Aneurysm Example Aneurysm Example We said since life expectancy is reduced by 2/3, so instead of 35, it is = 35 *.333 = We said since life expectancy is reduced by 2/3, so instead of 35, it is = 35 *.333 = However, are all years considered equal? However, are all years considered equal? Consider: Favorite Meal Consider: Favorite Meal Extreme Pain Lifetime Income

Outcomes - Discounting Generally, present > future Generally, present > future One common way to value the different times is discounting One common way to value the different times is discounting Essentially this year is worth δ more than next year Essentially this year is worth δ more than next year δ is commonly set at 0.03 or 3% δ is commonly set at 0.03 or 3% In order to compare values of all future times, a calculation, net present value, is often used In order to compare values of all future times, a calculation, net present value, is often used NPV = 1 / (1 + δ) t Where t is number of years in the future NPV = 1 / (1 + δ) t Where t is number of years in the future

Outcomes - Discounting Aneurysm Example Aneurysm Example If utility is 0.6 and life expectancy is 3 years If utility is 0.6 and life expectancy is 3 years NPV would be:  Utility / (1 + δ) t NPV would be:  Utility / (1 + δ) t However, when is year 1? However, when is year 1? Often, since events in year one occur on average half way through, we use 0.5 for year 1 NPV = 0.6 / (1.03) / (1.03) / (1.03) 2.5 NPV = 0.6 / (1.03) / (1.03) / (1.03) 2.5 NPV = 0.6 * {(1.03) (1.03) (1.03) -2.5 } NPV = 0.6 * {(1.03) (1.03) (1.03) -2.5 }

Outcomes - Discounting

Exponential Discounting Exponential discounting first described in 1937* Mathematically easy to manipulate Assumed discounting in “simple regular fashion” Does not differentiate difference between: Today vs. tomorrow Ten years vs. ten years plus one day *Samuelson PA. A Note on Measurement of Utility. Rev Econ Stud 1937;4:155-61

Discounting – Special Topic Think about your favorite dessert. Think about your favorite dessert. How much would you pay to have now? How much would you pay to have now? How much would pay to have tonight? How much would pay to have tonight? How much would you pay to have in 1 yr? How much would you pay to have in 1 yr? How much would you pay in 1 yr and 1 day? How much would you pay in 1 yr and 1 day?

Exponential Discounting Problems with the Model Discounting unlikely to be constant Anticipal effect is not demonstrated Difference in valuations appears greater when closer Discount reversal effects not incorporated Far future, prefer A to B Near future, prefer B to A

Discounting – Special Topic Solutions: Measure discount rates through life Could model with present-biased preferences Essentially, “today” versus all other time periods is valued higher for many outcomes Difference in future outcomes is likely similar

Present-Biased Preferences Described by: Phelps and Pollack in 1968* O’Donoghue and Rabin in 1999** Two parameter model***: β – the difference between today and “tomorrow” δ – the difference between all future time intervals Model accounts for Discount reversal effects Component of anticipal effects *Phelps ES, Pollack RA. On Second-Best National Saving and Game-Equilibrium Growth. Rev Econ Studies 1968;35: **O’Donoghue T, Rabin M. Doing it Now or Later. Amer Econ Rev 1999;89: *** Laibson D. Golden Eggs and Hyperbolic Discounting. QJE 1997;112:443-77

Exponential vs. PBP Exponential: U T = U P (outcome) + Σn δ n U P (outcome) Present-biased preferences: U T = U P (outcome) + β[Σn δ n U P (outcome)] U T is the total NPV utility U P is the moment to moment utility β gives difference between immediate and all other time periods, while δ is difference in the future

Discounting: Prescriptive vs. Descriptive We discount We discount But, should we But, should we Example - perceived time Example - perceived time

Overall Review Outcomes OutcomesMortalityMorbidity Measuring Utilities Measuring Utilities Visual Analog Standard Gamble Time Trade-off Quality Adjusted Life Years (QALYs) Quality Adjusted Life Years (QALYs) QALYs = time (years) x quality (utils) QALYs = time (years) x quality (utils) Discounting Discounting NPV =  Utility / (1 + δ) t